Should you buy stock in CoreWeave right now?
Before you buy stock in CoreWeave, consider this:Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end
Key PointsPayPal raised its full-year adjusted earnings guidance after releasing its third-quarter 2026 results, as the new CEO pushes for a broad turnaround.
(RTTNews) - Drugmaker Pfizer Inc. (PFE) announced on Wednesday that it has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics for three preclinical in vivo CAR-T programs targeting autoimmune diseases.
(RTTNews) - J & J Snack Foods Corp. (JJSF) said it expects to return to top-line growth in fiscal 2027 through core volume growth, innovation and pricing. The company said the next phase of Project Apollo is expected to generate an incremental $5 million in annualized run rate sa
Should you buy stock in Bloom Energy right now?
Before you buy stock in Bloom Energy, consider this:Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at th
(RTTNews) - Rockwell Automation, Inc. (ROK), an industrial automation and information company, on Wednesday announced that it has signed a definitive agreement to acquire Austria-based Agilox, a manufacturer of autonomous mobile robots or AMRs.
In recent trading, shares of Guardian Pharmacy Services Inc (Symbol: GRDN) have crossed above the average analyst 12-month target price of $50.14, changing hands for $50.33/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: do